Bizarre Patents
An extension member is attachable to a trailer hitch and extends away from the vehicle and is connected to a seating frame supporting a toilet seat.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 7153589 | Mo-W material for formation of wiring, Mo-W target and method for production thereof, and Mo-W wiring thin film A Mo—W material for the formation of wirings is discloses which, as viewed integrally, comprises 20 to 95% of tungsten and the balance of molybdenum and inevitable impurities by atomic percentage. The Mo—W material for wirings is a product obtained by compoundin... | 12/26/2006 |
| 7094401 | HCV core protein binding agents for treatment of hepatitis C virus infection The present invention provides a method of treating or preventing hepatitis C virus infection in a subject which comprises administering an effective amount of an agent to the subject, wherein the agent is capable of specifically binding to the HCV core protein so a... | 08/22/2006 |
| 7071319 | Recombinant antibodies, and compositions and methods for making and using the same Recombinant antibodies are disclosed. The nucleic acid and encoded amino acid sequences of the heavy and light chain immunoglobulins of human monoclonal rabies virus neutralizing antibodies, and their use, are described. ... | 07/04/2006 |
| 7041300 | Vectors based on recombinant defective viral genomes, and their use in the formulation of vaccines The vectors comprise a recombinant defective viral genome expressing at least one antigen suitable for the induction of systemic and secretory immune responses or an antibody conferring protection against an infectious agent. The defective viral genome comprises the... | 05/09/2006 |
| 7037644 | Means and methods for monitoring non-nucleoside reverse transcriptase inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of HIV/AIDS This invention relates to antiviral drug susceptibility and resistance tests to be used in identifying effective drug regimens for the treatment of human immunodeficiency virus (HIV) infection and acquired immunodeficiency syndrome (AIDS) and further relates to the ... | 05/02/2006 |
| 7029676 | Methods and compositions for modulating heterotypic E-cadherin interactions with T lymphocytes The present invention relates to methods and compositions for modulating the heterotypic adhesion between E-cadherin expressing cells and T lymphocytes. Monoclonal antibodies which specifically bind to E-cadherin and isolated peptides which mimic the binding functio... | 04/18/2006 |
| 7014855 | Prevention and treatment of amyloidogenic disease The invention provides compositions and methods for treatment of amyloidogenic diseases. Such methods entail administering an agent that induces a beneficial immune response against an amyloid deposit in the patient. The methods are particularly useful for prophylac... | 03/21/2006 |
| 7008784 | Non-infectious, non-replicating, immunogenic human immunodeficiency virus-like particles The present invention is directed toward methods for the production of non-infectious, replication-deficient, immunogenic human immunodeficiency virus (HIV)-like particles. These particles are prepared from a recombinant expression vector comprising a heterologous p... | 03/07/2006 |
| 7001760 | Hepatitis B virus vectors for gene therapy The present invention relates to novel hepatitis B virus vectors for use in gene therapy which can deliver therapeutic genes to liver cells. The invention also provides methods for the production of novel recombinant hepatitis B viruses. The recombinant viruses prod... | 02/21/2006 |
| 6991929 | Hepatitis A vaccines A process for the production of inactivated Hepatitis A virus substantially free of host cell contamination is described, the process comprising: a) culturing Hepatitis A virus and harvesting a Hepatitis A preparation; b) treating said Hepatitis A preparation with a... | 01/31/2006 |
| 6984386 | Nanoscale particles synthesized within an assembled virion Virion-constrained nanoparticles comprising a shell of virion coat protein(s) surrounding an organic, inorganic and/or organo-metallic non-viral nanoparticle and methods of making and using. ... | 01/10/2006 |
| 6982084 | Prevention and treatment of amyloidogenic disease The invention provides compositions and methods for treatment of amyloidogenic diseases. Such methods entail administering an agent that induces a beneficial immune response against an amyloid deposit in the patient. The methods are particularly useful for prophylac... | 01/03/2006 |
| 6977164 | Compositions and kits for Herpes Simplex Virus type 1 and 2 nucleic acid detection The invention relates to polynucleotides for HSV detection and the use of these polypeptides in kits and methods for HSV detection. ... | 12/20/2005 |
| 6974577 | Inactivated bovine scours vaccines, processes and method of preventing bovine scours Inactivated scours vaccines for immunization and protection of bovine animals from disease caused by infection with bovine rotavirus and bovine coronavirus, which comprise and effective amount of at least one inactivated viral strain are described. Polyvalent inacti... | 12/13/2005 |
| 6972127 | Prevention and treatment of amyloidogenic disease The invention provides compositions and methods for treatment of amyloidogenic diseases. Such methods entail administering an agent that induces a beneficial immune response against an amyloid deposit in the patient. The methods are particularly useful for prophylac... | 12/06/2005 |
| 6967075 | HCV replicase complexes This invention provides efficient HCV replicase complexes comprising novel RNA template and primer pair. Assay systems are also provided, which use such complexes, for detecting replicase activity, quantitatively studying the kinetics and mechanism of HCV NS5B-catal... | 11/22/2005 |
| 6964852 | Antigenic structural peptide, antigenic and immunogenic compounds, and uses for detecting, preventing and treating an HCV infection The invention concerns a structural peptide, identified by antibodies directed against a polypeptide, comprising the 2-45 amino acid sequence of the N-terminal end of the Core or nucleocapsid (p21) protein of the hepatitis C virus (HCV), excluding any protein or pep... | 11/15/2005 |
| 6962707 | Prevention and treatment of amyloidogenic disease The invention provides compositions and methods for treatment of amyloidogenic diseases. Such methods entail administering an agent that induces a beneficial immune response against an amyloid deposit in the patient. The methods are particularly useful for prophylac... | 11/08/2005 |
| 6958390 | Compositions and kits for herpes simplex virus type 1 and 2 nucleic acid detection The invention relates to polynucleotides for HSV detection and the use of these polypeptides in kits and methods for HSV detection. ... | 10/25/2005 |
| 6951717 | Methods and compositions for inhibition of membrane fusion-associated events, including HIV transmission Parainfluenza virus types 1 to 4 (PIV1 to PIV4) are important human pathogens that cause upper and lower respiratory tract infections, particularly in infants and children. The claimed invention is directed toward novel methods for the inhibition of parainfluenza vi... | 10/04/2005 |
| 6946136 | Temperature-sensitive and cold-adapted human parainfluenza virus type 2 (HPIV-2) and vaccines based on such virus The present invention relates to isolated, attenuated viral strains of human parainfluenza virus 2 (HPIV-2), which are useful in live vaccine preparations. These strains exhibit a temperature sensitive and cold adapted phenotype useful for stimulating a protective i... | 09/20/2005 |
| 6946264 | Metalloproteinase inhibitor A novel metalloproteinase inhibitor, analogs thereof, polynucleotides encoding the same, and methods of production, are disclosed. Pharmaceutical compositions and methods of treating disorders caused by excessive amounts of metalloproteinase are also disclosed. ... | 09/20/2005 |
| 6946135 | Prevention and treatment of amyloidogenic disease The invention provides compositions and methods for treatment of amyloidogenic diseases. Such methods entail administering an agent that induces a beneficial immune response against an amyloid deposit in the patient. The methods are particularly useful for prophylac... | 09/20/2005 |
| 6942965 | Hepatitis A virus nucleotide sequences, recombinant proteins and uses thereof Hepatitis A virus primers and probes derived from the capsid proteins and junction between the capsid precursor P1 and 2A of the HAV genome are disclosed. Also disclosed are nucleic acid-based assays using the primers and probes, antigen detection of HAV, and immuno... | 09/13/2005 |
| 6936257 | Recombinant Venezuelan equine encephalitis virus vaccine A prophylactic or therapeutic vaccine for use in protecting mammals such as humans or animals against Venezelan Equine Encephalitis virus (VEE) is described. In particular, the vaccine comprises a recombinant virus such as a recombinant vaccinia virus which is able ... | 08/30/2005 |
| 6930181 | Antigen associated with type 1 Diabetes Mellitus A 69 kD protein, designated PM-1, is expressed in human pancreatic islet cells and a human insulinoma. The amino acid sequence of the protein has been determined. Autoantibodies to the PM-1 protein have been found in sera of prediabetic patients. Natural, synthetic ... | 08/16/2005 |
| 6924368 | Variable region of the monoclonal antibody against the HBV S-surface antigen and a gene encoding the same The present invention relates to a variable region of the monoclonal antibody against the S-surface antigen of hepatis B virus and a gene encoding the same, a recombinant vector containing the said gene, and a transformant obtained from the said recombinant vector. | 08/02/2005 |
| 6919084 | Duck pneumovirus and corresponding vaccines An immunogenic preparation or vaccine against avian pneumovirosis, comprising an antigen of the avian pneumovirus strain C990427, in a vehicle or excipient which is acceptable from the veterinary point of view and, optionally, an adjuvant. ... | 07/19/2005 |
| 6908618 | Production of novel bovine respiratory syncytial viruses from cDNAs A method of producing an attenuated bovine respiratory syncytial virus (BRSV) having increased or decreased transcription and/or replication, as compared to a wild-type BRSV, including the steps of inserting a synthetic cDNA which codes for an infectious BRSV into a... | 06/21/2005 |
| 6908987 | PCG-1, a novel brown fat PPARγ coactivator The invention provides isolated nucleic acids molecules, designated PGC-1 nucleic acid molecules, which encode proteins which can modulate various adipocyte-associated activities including, for example, thermogenesis in adipocytes, e.g., brown adipocytes, and adipog... | 06/21/2005 |
| 6905677 | Combined hepatitis B treatment The invention relates to a method of treating patients infected with hepatitis B virus comprising the adminstration of both a nucleoside analogue and interferon-α over a prolonged period of time. ... | 06/14/2005 |
| 6900299 | Interrupting the interaction of intercellular adhesion molecule-1 and respiratory syncytial virus for prevention and treatment of infection There is provided a method of preventing a respiratory infection by administering an effective amount of an agent for regulating ICAM-1 expression. Also provided is a composition for the prevention of respiratory infection including an agent which regulates ICAM exp... | 05/31/2005 |
| 6890711 | Titration method for a complex viral composition The invention concerns a method for determining, in a composition containing different species of types of live viruses, the amount of viruses of each type or species, consisting in the following steps: propagating viruses of each type or species on cells permissive... | 05/10/2005 |
| 6890532 | Rabies virus-specific neutralizing human monoclonal antibodies and nucleic acids and related methods Human monoclonal rabies virus neutralizing antibodies represent a safe and efficacious post-exposure prophylactic therapy for individuals exposed to a rabies virus. The nucleic acid and encoded amino acid sequences of the heavy and light chain immunoglobulins of hum... | 05/10/2005 |
| 6884414 | Recombinant influenza viruses expressing tumor-associated antigens as antitumor agents The present invention relates to the engineering of recombinant influenza viruses that express tumor-associated antigens. Expression of tumor-associated antigens by these viruses can be achieved by engineering specific epitopes into influenza virus proteins, or by e... | 04/26/2005 |
| 6884629 | Immunoglobulin binding protein The present invention is directed to an immunoglobulin light chain binding protein which comprises the amino acid sequence of SEQ ID NO:1 modified by an amino acid substitution at one or more of positions 39, 53 and 57 and/or by an amino acid insertion between posit... | 04/26/2005 |
| 6872391 | PGC-1, a novel brown fat PPARγ coactivator The invention provides isolated nucleic acids molecules, designated PGC-1 nucleic acid molecules, which encode proteins which can modulate various adipocyte-associated activities including, for example, thermogenesis in adipocytes, e.g., brown adipocytes, and adipog... | 03/29/2005 |
| 6866850 | Prevention and treatment of amyloidogenic disease The invention provides compositions and methods for treatment of amyloidogenic diseases. Such methods entail administering an agent that induces a beneficial immune response against an amyloid deposit in the patient. The methods are particularly useful for prophylac... | 03/15/2005 |
| 6866849 | Prevention and treatment of amyloidogenic disease The invention provides compositions and methods for treatment of amyloidogenic diseases. Such methods entail administering an agent that induces a beneficial immune response against an amyloid deposit in the patient. The methods are particularly useful for prophylac... | 03/15/2005 |
| 6852324 | Immunization for ebola virus infection Ebola virus vaccines comprising nucleic acid molecules encoding Ebola viral proteins are provided. In one embodiment, the nucleic acid molecule encodes the transmembrane form of the viral glycoprotein (GP). In another embodiment, the nucleic acid molecule encodes th... | 02/08/2005 |
